Eleva, a company focused delivering difficult-to-produce biologics based on its proprietary manufacturing platform, and 3PBIOVIAN, a contract development and manufacturing organization (CDMO), have entered into an agreement to collaborate on the manufacturing of current pipeline programmes and potential future programmes based on Eleva’s technology platform.

Under the terms of the agreement, Eleva secures production capacity at 3PBIOVIAN for the clinical-grade material needed to advance its current pipeline programmes into mid- to late-stage clinical development. This covers Factor H (CPV-104), a novel complement modulator currently being developed in C3 Glomerulopathy (C3G) and dry age-related macular degeneration (dry AMD). Additionally, 3PBIOVIAN acquires a non-exclusive license to Eleva’s expression system.